Immune activity by radiofrequency ablation (RFA) in non-resected biliary tract cancer

Immune activity of radiofrequency ablation in patients with non-resected biliary tract cancer with obstructive jaundice

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1050230099

Enrollment

Registered

2023-09-09

Start date

2023-09-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Biliary tract cancer Biliary Tract Neoplasm, Biliary Tract Cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with biliary tract cancer with obstructive jaundice Patients who need endoscopic biliary drainage and are scheduled for stenting Patients over 20 years old Patients with unresectable biliary tract cancer Patients with performance status 2 or lower

Exclusion criteria

Exclusion criteria: Patients with bleeding tendency Patients with difficulty in endoscopic insertion Patients with difficulty in endoscopic biliary drainage Patients who are unable to give consent.

Design outcomes

Primary

Measure	Time frame
The expression levels of PD-1 , PD-L1, GAPDH, and CD8 genes in peripheral blood before and after RFA (1 day, 3 days, 1 week, and 14 days after treatment) will be measured and the gene levels will be observed.	—

Contacts

Public ContactYamashita Yasunobu

Wakayama Medical University Hospital

yasunobu@wakayama-med.ac.jp+81-73-447-2300

Outcome results